Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

Next Previous
Trial Profile

An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Levoketoconazole (Primary)
  • Indications Cushing syndrome
  • Focus Therapeutic Use
  • Acronyms OPTICS
  • Sponsors Strongbridge Biopharma; Xeris Biopharma Holdings

Most Recent Events

  • 08 Aug 2023 According to an Xeris Pharmaceuticals media release, the Research and development expenses increased by $2.4 million or 63.7% and $1.0 million or 9.6% for the three and six months ended June 30, 2023, respectively, compared to the same periods ended June 30, 2022. The increases in both periods were due to higher spending on the this study for Recorlev and higher product development costs.
  • 09 May 2023 Status changed from active, no longer recruiting to completed.
  • 31 Mar 2023 This trial has been completed in Greece (Date of the global end of the trial: 09-Jan-2023), according to the European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top